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Abstract: Coronavirus disease 2019 (COVID-19) infection causes acute lung injury, resulting from
aggressive inflammation initiated by viral replication. There has been much speculation about
the potential role of non-steroidal inflammatory drugs (NSAIDs), which increase the expression of
angiotensin-converting enzyme 2 (ACE2), a binding target for severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) to enter the host cell, which could lead to poorer outcomes in COVID-19
disease. The aim of this study was to examine the association between routine use of NSAIDs and
outcomes in hospitalised patients with COVID-19. This was a multicentre, observational study,
with data collected from adult patients with COVID-19 admitted to eight UK hospitals. Of 1222
patients eligible to be included, 54 (4.4%) were routinely prescribed NSAIDs prior to admission.
Univariate results suggested a modest protective effect from the use of NSAIDs, but in the multivariable
analysis, there was no association between prior NSAID use and time to mortality (adjusted HR
(aHR) = 0.89, 95% CI 0.52–1.53, p = 0.67) or length of stay (aHR 0.89, 95% CI 0.59–1.35, p = 0.58).
This study found no evidence that routine NSAID use was associated with higher COVID-19 mortality
in hospitalised patients; therefore, patients should be advised to continue taking these medications
until further evidence emerges. Our findings suggest that NSAID use might confer a modest benefit
with regard to survival. However, as this finding was underpowered, further research is required.
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1. Introduction
The pattern of acute lung injury seen in severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) infection—commonly referred to as coronavirus disease 2019 (COVID-19)—is
thought to be a result of aggressive inflammation initiated by viral replication; however, the exact
pathophysiology behind this phenomenon remains largely unknown [1]. Following recognition that
the angiotensin-converting enzyme 2 receptor (ACE2) serves as a binding site for SARS CoV-2 to
enter the host cell, a number of European authorities, including those in France and Belgium, issued
federal reports suggesting that the use of non-steroidal inflammatory drugs (NSAIDs) in the presence
of COVID-19 might adversely affect patients’ clinical course and recovery [2]. There remains, however,
a considerable uncertainty regarding the use of common NSAIDs and their effect on COVID-19.
NSAIDs are one of the most commonly prescribed and used pain medications worldwide,
for both acute pain and chronic conditions such as rheumatological diseases and osteoarthritis [3,4],
with analgesic, anti- inflammatory and anti-pyretic properties. The risks of NSAID use have been well
studied in the general population, with particular focus on the association between their long-term use
and increased risk of upper gastrointestinal effects (e.g., ulceration, bleeding), renal impairment and
arterial thrombotic events (e.g., myocardial infarction, stroke) [4]. It has been speculated that ibuprofen
may upregulate the cellular expression of ACE2 [5], and in the context of COVID-19, it is therefore
postulated that NSAID use could result in a higher viral infective load in the respiratory tract. More
recent work has also associated NSAIDs with high complication rates (effusion, empyema, dissemination
of infection) after acute respiratory tract infection [6,7], via NSAID-mediated cyclo-oxygenase (COX)
inhibition. It has been proposed that the inhibition of COX enzymes reduces the recruitment of
polymorphonuclear cells and inhibits the synthesis of lipoxins and resolvins, ultimately delaying the
resolution of inflammation.
However, there exists a conflict of opinion within the literature with regard to coronaviruses,
and very little research has been conducted to date. In vitro studies of the earlier SARS-CoV infection
in animal models and human lung epithelium found indomethacin to have potent antiviral activity
by inhibiting viral RNA synthesis [8], an effect that was independent of COX inhibition. Whilst the
anti-inflammatory properties of NSAIDs are well known, it is unclear what, if any, their effect is on
outcomes in patients with acute respiratory tract infection.
Available published evidence describing outcomes for patients with COVID-19 infection who
are NSAID users is specifically lacking. The primary aim of this study is therefore to examine the
association between prior routine use of NSAIDs and mortality and length of stay in patients with
COVID-19 admitted to hospital.
2. Methods
2.1. Study Population
The study population was drawn from the COPE (COVID-19 in Older People) study [9].
The COPE study is a multicentre, observational study governed by the Older Persons Surgical
Outcome Collaborative (OPSOC; www.opsoc.eu), our existing academic network of clinical centres.
OPSOC runs a well-established programme of research with experience in collecting epidemiological
data for both academic and service evaluation purposes. In the current study, a total of eight UK
centres were included. They were all involved in the delivery of unscheduled, in-patient treatment to
patients with COVID-19. Data were gathered between 6 March and 28 April 2020. Patient outcomes
were up to 28 April 2020. A detailed description of the study protocol and data collection methods has
been previously reported [9].
In brief, data collection was undertaken prospectively using a standardised, computerised
case report. This was populated after reviewing patients’ individual paper records, prescription
administration records and information from electronic records. Each site’s principal investigator
supervised the study personnel collecting data at a local level, all of whom had completed data
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collection training prior to their involvement in the study. Data were recorded securely at each site by
adherence to data protection policy, and collated data were ultimately transferred in an anonymised
format to King’s College London for statistical analysis.
2.2. Participants
Patients aged 18 years or older who were admitted to hospital with a clinical or laboratory
confirmed diagnosis of COVID-19 were included. Clinical diagnoses were made by clinicians at each
site, based on signs, symptoms and/or radiological appearance consistent with COVID-19, whilst
laboratory-confirmed diagnoses required positive PCR results from a swab test for SARS-CoV-2. There
were no exclusion criteria.
2.3. Endpoints
The primary endpoint was the time to mortality from the date of admission or date of diagnosis,
when the patient was diagnosed with COVID-19 five or more days after admission. Secondary
outcomes included day 7 mortality and the time from admission or diagnosis (if diagnosed a minimum
of five days after admission) to discharge (length of stay).
2.4. Exposure
Data on the use of NSAIDs, including the number, type and dose of anti-inflammatory that each
patient was taking prior to admission, were collected from admission records and from online GP
prescription records. NSAIDs included in the data collection were: propionic acid derivatives such as
ibuprofen and naproxen, diclofenac, an acetic acid derivative and selective COX-2 inhibitors such as
celecoxib. Topical NSAIDs such as ibuprofen gels were not included due to their low level of systemic
absorption and consequential limited systemic effects [10,11]. Low-dose aspirin was not included as
an NSAID in our data collection, as although it is a COX inhibitor, its effects are primarily anti-platelet
at low doses, with minimal anti-inflammatory effects. History of coronary artery disease was included
in the covariate data collection and adjusted for; the majority of these patients were taking aspirin.
2.5. Covariates
Additional clinical demographics collected included: age, sex, smoking status (current, previous,
never), C-reactive protein (CRP) levels on admission, reduced renal function (estimated glomerular
filtration rate (eGFR) < 60 on admission) and the presence of comorbidities including diabetes mellitus,
hypertension, and coronary artery disease (CAD).
2.6. Statistical Analysis
Baseline demographic and clinical characteristics were compared by in-hospital mortality status
and NSAID consumption versus lack of it. Time-to-event outcomes (death or discharge) were analysed
with mixed-effects multivariable Cox’s proportional baseline hazards models. The analyses were fitted
with a random intercept to account for hospital variation and adjusted for the base model of: NSAID
prescribed (yes/no), patient age group, sex, smoking status, CRP levels, diabetes, hypertension, coronary
artery disease, reduced renal function (eGFR < 60). The adjusted hazard ratios (aHR) were estimated
with associated 95% confidence intervals (95% CI). The baseline proportionality assumption was tested
visually with log-log residuals. Each time-to-event analysis was reported with a Kaplan–Meier survival
plot. Day 7 mortality was analysed using a mixed-effects multivariable logistic model, fitting each
hospital as a random intercept effect, and adjusted with covariates consistent with the time-to-event
analyses. The adjusted odds ratios (aOR) were estimated and presented with corresponding 95%
confidence interval (95% CI). Missing data were explored for patterns of missingness. Subgroup
analyses were carried out to explore potentially moderating effects of NSAID use within different
subgroups stratified by age group, sex, smoking status, diabetes, hypertension, coronary artery disease
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and renal impairment. Analysis was carried out using Stata version 15 [12]; Kaplan–Meier survival
plots were visualised in R [13], with packages survival [14] and survminer [15].
Permission to undertake the study was received from The Health Research Authority
(20/HRA/1898); Cardiff University acted as study sponsor.
3. Results
Data were collected from 1222 patients with COVID-19 across eight UK sites, of whom 56.5%
(n = 690) were male. Of these patients, 4.4% (n = 54) were prescribed routine NSAIDs prior to admission.
There were 19 patients with missing CRP data, inputted as CRP < 40, and a further 20 patients with
missing smoking status, who were recorded as ‘never smokers’. Overall in-hospital mortality was
29.3% (n = 358), varying from 12.2 to 43.9% across hospital sites. In-hospital mortality was 25.9%
(n = 14) for the NSAID users and 29.5% (n = 344) among the non-users (p = 0.578). In-hospital mortality
was higher in older age groups (39% in patients aged ≥80 years; 34.3% in those aged 65–79 years; 12.9%
in patients aged <65 years) and for patients with co-morbidities including diabetes (32.4% in patients
with diabetes vs. 28.1% in those without), hypertension (32.6% vs. 25.7%), coronary artery disease
(39.2% vs. 26.3%) and reduced renal function (eGFR < 60) on admission (38.7% vs. 23.1%). A complete
breakdown of demographics and clinical characteristics by in-hospital mortality is shown in Table 1.




(n = 864) (n = 358) (n = 1222)
NSAID Prescription
0.578No 824 (70.6) 344 (29.5) 1168 (95.6)
Yes 40 (74.1) 14 (25.9) 54 (4.4)
Sites
<0.001
Hospital A 119 (77.8) 34 (22.2) 153 (12.5)
Hospital B 33 (76.7) 10 (23.3) 43 (3.5)
Hospital C 108 (87.8) 15 (12.2) 123 (10.1)
Hospital D 254 (66.8) 126 (33.2) 380 (31.1)
Hospital E 76 (67.9) 36 (32.1) 112 (9.2)
Hospital F 138 (56.1) 108 (43.9) 246 (20.1)
Hospital G 100 (87.0) 15 (13.0) 115 (9.4)
Hospital H 36 (72.0) 14 (28.0) 50 (4.1)
Age
<0.001
Under 65 years 337 (87.1) 50 (12.9) 387 (31.7)
65 to 79 years 266 (65.7) 139 (34.3) 405 (33.1)
Over 80 years 261 (60.7) 169 (39.3) 430 (35.2)
Sex
0.625Female 380 (71.4) 152 (28.6) 532 (43.5)
Male 484 (70.1) 206 (29.9) 690 (56.5)
Smoking Status
0.049
Never smokers 453 (73.2) 166 (26.8) 619 (50.7)
Ex-smokers 325 (66.7) 162 (33.3) 487 (39.9)
Current smokers 74 (77.1) 22 (22.9) 96 (7.8)
Missing 12 8 20
Diabetes
0.100
No 638 (71.9) 249 (28.1) 887 (72.6)
Yes 223 (67.6) 107 (32.4) 330 (27.0)
Missing 3 2 5




(n = 864) (n = 358) (n = 1222)
Hypertension
0.008
No 448 (74.3) 155 (25.7) 603 (49.4)
Yes 414 (67.4) 200 (32.6) 614 (50.3)
Missing 2 3 5
Coronary Artery disease
<0.001
No 696 (73.7) 248 (26.3) 944 (77.3)
Yes 166 (60.8) 107 (39.2) 273 (22.3)
Missing 2 3 5
Elevated CRP (>40)
<0.001
No 282 (84.4) 52 (15.6) 334 (27.3)
Yes 571 (65.7) 298 (34.3) 869 (72.7)
Missing 11 8 19
Renal function (eGFR < 60)
<0.001
No 568 (76.9) 171 (23.1) 739 (60.5)
Yes 290 (61.3) 183 (38.7) 473 (38.7)
Missing 6 4 10
& Chi-square test was carried out between clinical characteristics and mortality.
Overall, NSAID use in the study population was 4.4% (n = 54), ranging from 2.6 to 18.6% across
the eight hospital sites. Pre-admission NSAID use was higher in the younger age groups (<65 years,
6.5%; 65–79 years, 4.2%; ≥ 80 years, 2.8%) and lower in patients with co-morbidities including diabetes
(3.3% in diabetic patients vs. 4.9% in non-diabetics), hypertension (2.8% vs. 6.1%), coronary artery
disease (3.3% vs. 4.8%) and reduced renal function (3.0% vs. 5.4%). The routine prescription of NSAIDs
was higher for patients with an elevated CRP level on admission; in fact, 5.1% of patients with an
elevated CRP level (>40 mg dL−1) were prescribed routine NSAIDs prior to admission, compared to
3% of those without an elevated CRP value. Full patient demographics and clinical characteristics by
NSAID use are shown in Table A1.
Outcome Analysis
The primary endpoint was time to mortality. The Kaplan–Meier Survival plot suggested a modest
protective effect of NSAID use (Figure 1, Kaplan–Meier curves), but in the crude analysis with 95%
CI, we found no association between the routine use of NSAIDs and time to mortality, hazard ratio
(HR) = 0.82 (95% CI 0.48–1.40, p = 0.46, Table 2; indicated by overlapping shaded areas in Figure 1).
Important covariates which have previously been linked to poorer outcomes in COVID-19 patients
were associated with a reduced time to mortality. These included: advancing age (compared to patients
aged <65 years: patients aged 65–79 years, HR = 3.21, 95% CI 2.29–4.51; patients aged over 80 years,
HR = 3.94, 95% CI 2.52–5.50), reduced renal function (eGFR < 60) on admission (HR = 1.80, 95% CI
1.45–2.24, p < 0.001) and the presence or history of coronary artery disease (HR = 1.47, p = 0.001) and
hypertension (HR = 1.27, 95% CI 1.03–1.58, p = 0.03).
In the multivariable analysis, there was no association between pre-admission NSAID use and
time to mortality (adjusted HR (aHR) = 0.89, 95% CI 0.52–1.53, p = 0.67, Table 2). Advancing age
(65–79 years vs. under 65 years, aHR = 3.14, 95% CI 2.20–4.48, p < 0.001; over 80 vs. under 65;
aHR = 4.00, 95% CI 2.81–5.71, <0.001), elevated CRP level (>40 mg/dL; aHR = 2.75, 95% CI 2.01–3.76,
p < 0.001) and reduced renal function on admission (eGFR < 60; aHR = 1.40, 95% CI 1.11–1.75, p = 0.004)
were associated with mortality.
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Figure 1. NSAID use and mortality (shaded areas indicate 95% confidence intervals).
Table 2. Time to mortality. Crude and multivariable analysis.
Crude Hazard Ratio (HR) Adjusted Hazard Ratio (aHR) &
(n = 1181) (n = 1167)
HR, (95% CI) p-Value aHR, (95% CI) p-Value
NSAID 0.82 (0.48–1.40) 0.46 0.89 (0.52–1.53) 0.67
Age
Under 65 -Ref- -Ref-
65 to 79 3.21 (2.29–4.51) <0.001 3.14 (2.20–4.48) <0.001
Over 80 3.94 (2.82–5.50) <0.001 4.00 (2.81–5.71) <0.001
Sex
Female -Ref- -Ref-
Male 0.88 (0.71–1.10) 0.25 0.88 (0.70–1.11) 0.28
Smoking status
Never
Ex-smokers 1.24 (1.0–1.55) 0.06 1.02 (0.80–1.28) 0.92
Current smokers 0.90 (0.56–1.42) 0.62 1.11 (0.68–1.82) 0.66
Elevated CRP (>40) 2.24 (1.65–3.05) <0.001 2.75 (2.01–3.76) <0.001
Patients with diabetes 1.09 (0.87–1.38) 0.45 1.03 (0.81–1.32) 0.80
Patients with CAD 1.47 (1.16–1.87) 0.001 1.09 (0.84–1.40) 0.53
Patients with hypertension 1.27 (1.03–1.58) 0.03 0.97 (0.77–1.22) 0.81
Patients with reduced renal
function (eGFR < 60) 1.80 (1.45–2.24) <0.001 1.40 (1.11–1.76) 0.004
& The multivariable mixed-effects analysis was adjusted for age group, sex, smoking, C–reactive protein (CRP) level,
diabetes, coronary artery disease (CAD), hypertension and renal function; eGFR, estimated glomerular filtration rate.
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In the analysis for secondary outcomes, no association was found between pre-admission NSAID
use and day-7 mortality (aOR = 0.79, p = 0.60, Table 3) or time to discharge (aHR = 0.89, 95% CI
0.59–1.35, p = 0.58, Table 3). Day-7 mortality was associated with older age (compared to patients aged
<65 years: 65–79 years aOR = 3.80, p < 0.001; ≥80 years aOR = 5.14, p < 0.001), elevated CRP level on
admission (aOR = 4.91, p < 0.001) and reduced renal function (aOR = 2.02, p < 0.001). An increased
length of stay was associated with older age and elevated CRP on admission (see Table 3).
Table 3. Day-7 mortality and time to discharge. Multivariable analysis.
Adjusted Odds Ratio (OR) Adjusted Hazard Ratio (aHR) &
(n = 1158) (n = 1167)
aOR, (95% CI) p-Value aHR, (95% CI) p-Value
NSAID 0.79 (0.32–1.92) 0.602 0.89 (0.59–1.35) 0.58
Age
Under 65 -Ref- -Ref-
65 to 79 3.80 (2.26–6.37) <0.001 0.76 (0.61–0.95) 0.02
Over 80 5.14 (3.04–8.69) <0.001 0.56 (0.44–0.73) <0.001
Sex
Female -Ref- -Ref-
Male 0.81 (0.57–1.14) 0.227 0.92 (0.76–1.11) 0.37
Smoking status
Never
Ex-smokers 1.17 (0.83–1.67) 0.372 0.95 (0.78–1.15) 0.61
Current smokers 1.12 (0.54–2.33) 0.765 1.04 (0.73–1.48) 0.84
Elevated CRP (>40) 4.91 (2.99–8.06) <0.001 0.69 (0.57–0.84) <0.001
Patients with diabetes 1.04 (0.71–1.52) 0.838 0.84 (0.68–1.04) 0.12
Patients with CAD 1.46 (1.00–2.13) 0.051 1.12 (0.88–1.42) 0.36
Patients with hypertension 0.78 (0.55–1.10) 0.157 0.95 (0.79–1.16) 0.63
Patients with reduced renal
function (eGFR < 60) 2.02 (1.42–2.86) <0.001 0.92 (0.75–1.13) 0.58
& The multivariable mixed-effects analysis was adjusted for age group, sex, smoking, CRP level, diabetes, CAD,
hypertension and renal function.
Figures A1–A3 show subgroup analysis for patients prescribed NSAIDs in relation to the three
endpoints, i.e., time to mortality, day-7 mortality and length of stay. Hazards ratios and odds ratios
were adjusted for age group, sex, smoking status and co-morbidities. Due to the small number of
NSAID users in our study population, these analyses were underpowered and should be interpreted
with caution and with a large degree of uncertainty.
4. Discussion
To the best of our knowledge, this study is the first to report on routine NSAID use and outcomes
in hospitalized patients with COVID-19. We found that the routine use of NSAIDs might confer a
modest survival benefit and is not associated with poorer outcomes. Uncertainty and speculation have
surrounded this topic, and existing literature primarily references experience of these drugs in the
setting of previous respiratory virus outbreaks [16]. Therefore, our findings provide novel information
at a time where there is a significant lack of evidence and high demand for knowledge.
Whilst systematic reviews have concluded that there is insufficient evidence to determine the
effect of NSAIDs in COVID-19 patients [16–19], advising against drastic changes to drug regimens,
alternative literature recommends that NSAIDs should be avoided until evidence emerges [20]. Many
of the studies referenced within literature reviews are in relation to respiratory viruses other than
SARS-CoV-2. It is thought that the pathophysiology and transmission of COVID-19 shows differences
in behaviour even from other viruses within its family, such as SARS-CoV and Middle Eastern
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respiratory syndrome (MERS) virus [19]. Therefore, the findings of these studies may not be applicable
to COVID-19. However, very recently Rinott et al. [21] published a retrospective cohort study of
403 cases of COVID-19 patients, recruiting those who used “any medication containing ibuprofen,
paracetamol or dipyrone starting a week before diagnosis of COVID-19”. Their conclusions therefore
address the issue of acute use of NSAIDs and found no significant association between ibuprofen
usage and clinical outcomes (including mortality) when comparing the NSAID group with cohorts
using paracetamol or no antipyretic.
Pre-admission NSAID use was lower in older age groups, which is in line with a recent European
study of NSAID epidemiology [22]. NSAIDS account for 25% of adverse drug events reported in the
United Kingdom [23], and it is thought that the elderly are more susceptible to the adverse effects
of these drugs [4]. Conversely, the higher percentage of NSAID use in younger adults in this study
may reflect their relative co-morbidity and subsequent susceptibility to hospitalisation as a result
of COVID-19.
Pre-admission NSAID use was also found to be lower in patients with co-morbidities across all
age groups. This may be due to the relative contraindication of NSAIDs in these patients [24] and
potential for drug interactions [25]. This low prevalence of NSAIDs routine use may be related to the
presence of background respiratory illness in a high proportion of patients with COVID-19, which
was a contraindication to their use. In the analysis of biochemical markers, the routine prescription
of NSAIDs was associated with elevated CRP level on admission. This was expected and is likely a
reflection of pre-existing inflammatory conditions, in addition to COVID-19 infection, that required
regular NSAID usage in this patient group.
The limitations of this study include a relatively small number of NSIAD users in our cohort;
thus, this study may be underpowered. It is possible that patients who had been using over-the-counter
NSAIDs were not captured. Conversely, as we collected data from prescriptions, it is possible that
some of the patients prescribed NSAIDs were not actually taking them in the days or weeks leading
up to admission. We did not collect data on indication for or duration of use of the agents, hence we
cannot rule out possible confounding by indication.
There are intrinsic limitations associated with any observational study. However, the prospective
relationship described reduces the possibility of reverse causality, whilst unselected cohort design
reduced the selection bias. This study did not take into consideration a proportion of patients who
were discharged from or died in the Emergency Department or those patients with COVID-19 who
remained in the community and were not treated in hospital. It is worth highlighting that our results
specifically apply to the routine use of NSAIDs by patients who then develop COVID-19. Our results
therefore do not signify the safety of an acute use of NSAIDs in the context of COVID-19. This calls for
future work examining the relationship between NSAID usage, by indication and duration as well as
routine or acute usage, and mortality of COVID-19 patients in a high-powered study.
Our study has several strengths. It was a multi-centre, prospective study, providing a large
study population, which included patients from a range of specialties including medicine, surgery
and medicine for the elderly. Through the inclusion of eight UK sites, the data are representative of
populations across England, Scotland and Wales. Data were collected by trained personnel from paper
and electronic records and prescription charts, which resulted in minimal missing data.
This study has a number of direct implications on both clinical practice and research. Based on our
results, patients and clinicians should not associate the routine use of NSAIDs with an increased risk of
mortality in COVID-19 patients; therefore, we recommend that patients continue to comply with their
baseline drug regimen. The association between NSAIDs and mortality in patients with COVID-19
warrants investigation via randomised controlled trials, as a method of further examining the potential
beneficial effects that this study has suggested. Indeed, the LIBERATE Trial in COVID-19 [26] is
an ongoing, multi-centre randomised controlled trial for lipid ibuprofen treatment versus standard
of care for acute hypoxic respiratory failure due to COVID-19. This is primarily in a critical care
setting. However, future investigation should not only concentrate on the use of NSAIDs as a
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therapeutic option but also continue to explore the effects of pre-admission NSAID use on outcomes
and mortality in the general population affected by COVID-19. Future, more highly powered studies
would more reliably comment on the association of type, dose and duration of NSAID therapy with
these important outcomes.
Our findings show no significant negative effect of routine NSAID use on mortality in patients with
COVID-19. Indeed, a modest beneficial effect of routine NSAID use on mortality may well exist, though
it cannot be concluded from the evidence presented here. This study provides novel information
about the impact of NSAID use on outcomes of COVID-19, during a pandemic characterised by much
uncertainty. Further evidence is required to explore this possible correlation and subsequently guide
public health policy.
Author Contributions: Conceptualization, P.K.M, J.H., B.C. and K.M.; methodology, P.K.M., B.C.; software, B.C.,
R.S.; validation, B.C., R.S.; formal analysis, R.S.; investigation, E.B., F.B.-P.; resources, J.H., P.K.M.; data curation,
E.B., F.B.-P., R.S., A.V.-M., A.P., A.M., M.J.S., S.M., K.M., J.H., B.C., P.K.M.; writing—original draft preparation, E.B.,
F.B.-P., B.C., P.K.M.; writing—review and editing, E.B., F.B.-P., R.S., A.V.-M., A.P., A.M., M.J.S., S.M., K.M., J.H.,
B.C., P.K.M.; visualization, E.B., F.B.-P., R.S., A.V.-M., A.P., A.M., M.J.S., S.M., K.M., J.H., B.C., P.K.M.; supervision,
P.K.M., A.V.-M., P.B., S.M.; project administration, E.B.; funding acquisition, Not applicable. All authors have read
and agreed to the published version of the manuscript.
Funding: This research received no external funding.
Acknowledgments: We gratefully acknowledge the collaborators of the study listed below: Ross Alexander,
Emma Bhatti, Carly Bisset, Alice Cavenagh, Jemima Collins, Charlotte Davey, Siobhan Duffy, Jenny Edwards,
Alice G Einarsson, Norman Galbraith, Madeline Garcia, James Hesford, Mark Holloway, Tarik Jichi, Joanna Kelly,
Sheila Jones, Thomas Kneen, Thomas Lee, Kiah Lunstone, Emma Mitchell, Dolcie Paxton, Lyndsay Pearce, Terence
J Quinn, Frances Rickard, Shefali Sangani, Rebecca Simmons, Sandeep Singh, Charlotte Silver, Thomas Telford,
Alessia Verduri.
Conflicts of Interest: The authors declare no conflict of interest.
Appendix A
Table A1. Demographics and comorbidities by NSAID use.
No Yes
Total
(n = 1168) (n = 54)
Sites
Hospital A 146 (95.4) 7 (4.6) 153 (12.5)
Hospital B 35 (81.4) 8 (18.6) 43 (3.5)
Hospital C 117 (95.1) 6 (4.9) 123 (10.7)
Hospital D 366 (96.3) 14 (3.7) 380 (31.1)
Hospital E 109 (97.3) 3 (3.0) 112 (9.2)
Hospital F 235 (95.5) 11 (4.5) 246 (20.1)
Hospital G 112 (97.4) 3 (2.6) 115 (9.4)
Hospital H 48 (96.0) 2 (4.0) 50 (4.1)
Age
Under 65 yrs 362 (93.4) 25 (6.5) 387 (31.7)
65 to 79 yrs 388 (95.8) 17 (4.2) 405 (33.1)
Over 80 yrs 418 (97.2) 12 (2.8) 430 (35.2)
Sex
Female 503 (94.6) 29 (5.5) 532 (43.5)
Male 665 (96.4) 25 (3.6) 690 (56.5)
Smoking Status
Never smokers 585 (94.5) 34 (5.5) 619 (50.7)
Ex-smokers 475 (97.5) 12 (2.5) 487 (39.9)
Current smokers 88 (91.7) 8 (8.3) 96 (7.9)
Missing 20 0 20




(n = 1168) (n = 54)
Diabetes
No 844 (95.2) 43 (4.9) 887 (72.6)
Yes 319 (96.7) 11 (3.3) 330(27.0)
Missing 5 0 5
Hypertension
No 566 (93.9) 37 (6.1) 603 (49.4)
Yes 597 (97.2) 17 (2.8) 614 (50.3)
Missing 5 0 5
Coronary Artery disease
No 899 (95.2) 45 (4.8) 944 (77.3)
Yes 264 (96.7) 9 (3.3) 273 (22.3)
Missing 5 0 5
Elevated CRP (>40)
No 324 (97.0) 10 (3.0) 334 (27.3)
Yes 825 (94.9) 44 (5.1) 888 (71.1)
Missing 19 0 19
Renal function (eGFR < 60)
No 699 (94.6) 10 (5.4) 739 (60.5)
Yes 459 (97.0) 14 (3.0) 473 (38.7)
Missing 10 0 10
Figure A1. Subgroups: time to mortality, adjusted hazard ratio are presented from the multivariable
Cox PH model. Note: multivariable analyses adjusted for age group, sex, smoking status, hypertension,
diabetes, CAD, kidney function and elevated CRP level.
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Figure A2. Subgroup analysis, day-7 mortality. Mixed effects logistic regression, presenting the
adjusted odds ratio from the logistic regression models. Note: multivariable analyses adjusted for age
group, sex, smoking status, hypertension, diabetes, CAD, kidney function and elevated CRP level.
Figure A3. Subgroups: time to discharge, adjusted hazard ratio are presented from the multivariable
Cox PH model. Note: multivariable analyses adjusted for age group, sex, smoking status, hypertension,
diabetes, CAD, kidney function, and elevated CRP level.
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